206 related articles for article (PubMed ID: 28678550)
1. The safety of albiglutide for the treatment of type 2 diabetes.
Rendell MS
Expert Opin Drug Saf; 2017 Sep; 16(9):1089-1097. PubMed ID: 28678550
[TBL] [Abstract][Full Text] [Related]
2. Albiglutide for the management of type 2 diabetes.
Rendell MS
Expert Rev Endocrinol Metab; 2018 Jan; 13(1):1-8. PubMed ID: 30063441
[TBL] [Abstract][Full Text] [Related]
3. Albiglutide: a unique GLP-1 receptor agonist.
Rendell MS
Expert Opin Biol Ther; 2016 Dec; 16(12):1557-1569. PubMed ID: 27677385
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.
Htike ZZ; Zaccardi F; Papamargaritis D; Webb DR; Khunti K; Davies MJ
Diabetes Obes Metab; 2017 Apr; 19(4):524-536. PubMed ID: 27981757
[TBL] [Abstract][Full Text] [Related]
5. Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists.
Madsbad S
Diabetes Obes Metab; 2016 Apr; 18(4):317-32. PubMed ID: 26511102
[TBL] [Abstract][Full Text] [Related]
6. Albiglutide: a new GLP-1 receptor agonist for the treatment of type 2 diabetes.
Trujillo JM; Nuffer W
Ann Pharmacother; 2014 Nov; 48(11):1494-501. PubMed ID: 25136065
[TBL] [Abstract][Full Text] [Related]
7. An overview of once-weekly glucagon-like peptide-1 receptor agonists--available efficacy and safety data and perspectives for the future.
Madsbad S; Kielgast U; Asmar M; Deacon CF; Torekov SS; Holst JJ
Diabetes Obes Metab; 2011 May; 13(5):394-407. PubMed ID: 21208359
[TBL] [Abstract][Full Text] [Related]
8. Comparative effectiveness of once-weekly glucagon-like peptide-1 receptor agonists with regard to 6-month glycaemic control and weight outcomes in patients with type 2 diabetes.
Unni S; Wittbrodt E; Ma J; Schauerhamer M; Hurd J; Ruiz-Negrón N; McAdam-Marx C
Diabetes Obes Metab; 2018 Feb; 20(2):468-473. PubMed ID: 28862808
[TBL] [Abstract][Full Text] [Related]
9. Long-acting GLP-1RAs: An overview of efficacy, safety, and their role in type 2 diabetes management.
Chun JH; Butts A
JAAPA; 2020 Aug; 33(S8 Suppl 1):3-18. PubMed ID: 32756220
[TBL] [Abstract][Full Text] [Related]
10. Glucagon-Like Peptide-1 Receptor Agonists for Type 2 Diabetes: A Clinical Update of Safety and Efficacy.
Drab SR
Curr Diabetes Rev; 2016; 12(4):403-413. PubMed ID: 26694823
[TBL] [Abstract][Full Text] [Related]
11. Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same?
Gentilella R; Pechtner V; Corcos A; Consoli A
Diabetes Metab Res Rev; 2019 Jan; 35(1):e3070. PubMed ID: 30156747
[TBL] [Abstract][Full Text] [Related]
12. Emerging new therapies for the treatment of type 2 diabetes mellitus: glucagon-like peptide-1 receptor agonists.
Lindamood CA; Taylor JR
Clin Ther; 2015 Mar; 37(3):483-93. PubMed ID: 25659912
[TBL] [Abstract][Full Text] [Related]
13. Albiglutide for the treatment of type 2 diabetes mellitus: An integrated safety analysis of the HARMONY phase 3 trials.
Ahrén B; Carr MC; Murphy K; Perkins C; Rendell M; Mallory J; Wilson T; Johnson S
Diabetes Res Clin Pract; 2017 Apr; 126():230-239. PubMed ID: 28284167
[TBL] [Abstract][Full Text] [Related]
14. Benefits and Harms of Once-Weekly Glucagon-like Peptide-1 Receptor Agonist Treatments: A Systematic Review and Network Meta-analysis.
Zaccardi F; Htike ZZ; Webb DR; Khunti K; Davies MJ
Ann Intern Med; 2016 Jan; 164(2):102-13. PubMed ID: 26642233
[TBL] [Abstract][Full Text] [Related]
15. Albiglutide for the treatment of type 2 diabetes.
Muscogiuri G; Gastaldelli A
Drugs Today (Barc); 2014 Oct; 50(10):665-78. PubMed ID: 25374965
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise.
Nauck MA; Stewart MW; Perkins C; Jones-Leone A; Yang F; Perry C; Reinhardt RR; Rendell M
Diabetologia; 2016 Feb; 59(2):266-74. PubMed ID: 26577795
[TBL] [Abstract][Full Text] [Related]
17. Albiglutide: A once-weekly glucagon-like peptide-1 receptor agonist for type 2 diabetes mellitus.
Davis PN; Ndefo UA; Oliver A; Payton E
Am J Health Syst Pharm; 2015 Jul; 72(13):1097-103. PubMed ID: 26092960
[TBL] [Abstract][Full Text] [Related]
18. GLP-1 receptor agonists for type 2 diabetes mellitus: recent developments and emerging agents.
Trujillo JM; Nuffer W
Pharmacotherapy; 2014 Nov; 34(11):1174-86. PubMed ID: 25382096
[TBL] [Abstract][Full Text] [Related]
19. Predictors of response to glucagon-like peptide-1 receptor agonists: a meta-analysis and systematic review of randomized controlled trials.
Monami M; Dicembrini I; Nreu B; Andreozzi F; Sesti G; Mannucci E
Acta Diabetol; 2017 Dec; 54(12):1101-1114. PubMed ID: 28932989
[TBL] [Abstract][Full Text] [Related]
20. User's guide to mechanism of action and clinical use of GLP-1 receptor agonists.
Shaefer CF; Kushner P; Aguilar R
Postgrad Med; 2015; 127(8):818-26. PubMed ID: 26371721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
